|
27 Feb 2019 |
Immunic Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of IMU-838, an Oral Therapy for Patients with Relapsing-Remitting Multiple Sclerosis
|
|
27 Feb 2019 |
ROMEG Therapeutics Receives FDA Approval of GLOPERBA® (colchicine) for Prophylaxis of Adult Gout Flares
|
|
27 Feb 2019 |
Acurx Announces First-In-Man Clinical Trial Data of ACX-362E for CDI
|
|
27 Feb 2019 |
Debiopharm International SA Initiates a Clinical Trial Phase II study evaluating afabicin in Bone and Joint Infections
|
|
27 Feb 2019 |
Inhibikase Therapeutics Files Two Investigational New Drug Applications for IkT-148009, a Disease-Modifying Therapy for Parkinson’s Disease
|
|
27 Feb 2019 |
Bayer completes rolling submission of New Drug Application to U.S. Food and Drug Administration for investigational drug darolutamide for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC)
|
|
27 Feb 2019 |
Eidos Therapeutics Initiates ATTRibute-CM, a Phase 3 Study of AG10 in ATTR-CM with Registrational 12-month Endpoint
|
|
27 Feb 2019 |
Minoryx Therapeutics receives approval from Spanish Regulatory Agency to initiate phase 2 study in Friedreich’s Ataxia
|
|
26 Feb 2019 |
BRILINTA’s Phase III THEMIS Trial Met Primary Endpoint in Patients with Established Coronary Artery Disease and Type-2 Diabetes
|
|
26 Feb 2019 |
Aptose Biosciences Submits IND Application for CG-806
|
|
26 Feb 2019 |
New data shows ALK’s house dust mite SLIT-tablet significantly improves quality of sleep for allergic rhinitis patients
|
|
26 Feb 2019 |
Lynparza significantly delayed disease progression as 1st-line maintenance treatment in germline BRCA-mutated metastatic pancreatic cancer
|
|
26 Feb 2019 |
FDA Approves Taiho Oncology’s LONSURF® (trifluridine/tipiracil) for Adult Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
|
|
25 Feb 2019 |
Bausch + Lomb Announces FDA Approval Of LOTEMAX SM (loteprednol Etabonate Ophthalmic Gel) 0.38% For The Treatment Of Postoperative Inflammation And Pain Following Ocular Surgery
|
|
25 Feb 2019 |
Santhera's SYROS Study Shows Long-term Efficacy with Idebenone in Slowing Respiratory Function Loss in Patients with Duchenne Muscular Dystrophy
|
|
25 Feb 2019 |
Alkermes and Biogen Announce U.S. Food and Drug Administration Acceptance of Diroximel Fumarate New Drug Application for Multiple Sclerosis
|
|
25 Feb 2019 |
Boehringer Ingelheim Completes Enrollment of Phase 2a Clinical Trial of Pharmaxis Developed Drug in NASH
|
|
24 Feb 2019 |
Dermira Initiates Proof-of-Concept Study to Evaluate QBREXZA™ (glycopyrronium) Cloth in Patients with Primary Palmar Hyperhidrosis
|
|
24 Feb 2019 |
Opiant Pharmaceuticals Announces Top-line Results from Phase 2 Clinical Trial of OPNT001 for Treatment of Bulimia Nervosa
|
|
24 Feb 2019 |
BioCryst Reports ZENITH-1 Results With Oral BCX7353 Which Confirm Rapid Onset of Action, Sustained Activity and Robust Dose Response for Treatment of Acute HAE Attacks
|
|
21 Feb 2019 |
First Patient Dosed in Complexa Phase 2 Trial of Lead Candidate CXA-10 to Treat Pulmonary Arterial Hypertension
|
|
21 Feb 2019 |
Magenta Therapeutics Presents Preclinical Data on MGTA-145, First-Line Stem Cell Mobilization Product Candidate for Autologous and Allogeneic Bone Marrow Transplant
|
|
21 Feb 2019 |
Amgen, Cytokinetics And Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure
|
|
21 Feb 2019 |
Koutif Therapeutics Announces FDA Acceptance of IND Application for Novel New Treatment of IBD
|
|
21 Feb 2019 |
Cytokinetics Announces Initiation of Phase 1 Clinical Study of AMG 594, a Cardiac Troponin Activator
|
